| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J8560 | Etoposide | Toposar | 50 mg | Chemotherapy | Plant Alkaloid | Epipodophyllotoxins | Yes | 1986 | Jan 1, 1995 | In Use | ||
| J1720 | Hydrocortisone Sodium Succinate | Cortef, Solu-CORTEF | 100 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1952 | Jan 1, 1997 | In Use | ||
| NA | Flutamide | Euflex, Eulexin | 125 mg | Hormonal Therapy | Androgen Receptor Inhibitor | Yes | 1989 | In Use | ||||
| J8600 | Melphalan | Melphalan, Alkeran | 2 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Yes | 1992 | Jan 1, 1995 | In Use | ||
| NA | Osimertinib | Tagrisso | 80 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2015 | In Use | |||
| NA | Dasatinib | Sprycel | 80 mg | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Yes | 2006 | In Use | |||
| NA | Vismodegib | Vismodegib | 150 mg | Chemotherapy | Hedgehog Pathway Inhibitor | SMO | Yes | 2012 | In Use | |||
| J9196 | Gemcitabine HCl (Accord) | Gemcitabine | 200MG | Chemotherapy | Antimetabolite | Pyrimidine Analog | No | 2011 | Mar 17, 2023 | In Use | ||
| J1675 | Histrelin Acetate | Supprelin LA, Vantas | 10 mcg | Hormonal Therapy | GnRH Agonist | No | 2004 | Jan 1, 2006 | In Use | |||
| NA | Pazopanib | Votrient | 200 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FGF, PDGFR,KIT, Lck, FMS | Yes | 2009 | In Use | |||
| NA | Selinexor | Xpovio | 20mg, 40mg, 50mg, 60mg | Chemotherapy | Enzyme Inhibitor | XPO1 | Yes | 2019 | In Use | |||
| J9226 | Histrelin Acetate | Supprelin LA | 50 mg | Hormonal Therapy | GnRH Agonist | No | 2004 | Jan 1, 2008 | In Use | |||
| NA | Osimertinib | Tagrisso | 40 mg | Chemotherapy | Tyrosine Kinase Inhibitor | EGFR | Yes | 2015 | In Use | |||
| NA | Sunitinib malate | Sutent | 25 mg | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR, FLT, PDGFR,KIT, RET, CSF | Yes | 2006 | In Use | |||
| Q5112 | Trastuzumab-dttb | Ontruzant | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2021 | Jul 1, 2019 | In Use | ||
| NA | Uridine Triacetate | Vistogard | 10 g | Ancillary Therapy | Chemoprotective | Antidote | Yes | 2015 | In Use | |||
| J9271 | Pembrolizumab | Keytruda | 1 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2014 | Jan 1, 2016 | In Use | ||
| J9316 | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf | Phesgo | 10mg | Immunotherapy | Monoclonal Antibody | HER2 | No | 2020 | Jan 1, 2021 | In Use | ||
| J1725 | Hydroxyprogesterone Caproate | Hydroxyprogesterone Caproate | 1 mg | Hormonal Therapy | Progestin | No | 2011 | Jan 1, 2012 | In Use | |||
| NA | Ivosidenib | Tibsovo | 250mg | Chemotherapy | Enzyme Inhibitor | IDH1 | Yes | 2018 | In Use | |||
| J3300 | Triamcinolone | Kenalog, Aristocort | 1 mg | Hormonal Therapy | Adrenal Glucocorticoid | Corticosteroid | No | 1960 | Jan 1, 2009 | In Use | ||
| NA | Trifluridine and Tipiracil | Lonsurf | 20/ 8.19 mg | Chemotherapy | Antimetabolite | Pyrimidine Analog | Yes | 2015 | In Use | |||
| J3489 | Zoledronic acid | Zometa (4 mg/5 ml) | 1 mg | Ancillary Therapy | Bisphosphonate | No | 2001 | Jan 1, 2014 | In Use | |||
| NA | idelalisib | Zydelig | 100 mg | Chemotherapy | Enzyme Inhibitor | PI3K | Yes | 2014 | In Use | |||
| NA | Estradiol | Estrace | 2 mg | Hormonal Therapy | Estrogen | Yes | 1998 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home